Physician profile
Greg Roy Cabrera
NPI 1417913815
$2,695.52
in general payments reported to CMS, 2019-2025
26 companies · $470 in 2025
The $470 reported for 2025 was more than what 93% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $167 · 2020: $181 · 2021: $421 · 2022: $427 · 2023: $388 · 2024: $640 · 2025: $470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,499.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,498.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $487.11 | 2024-2025 | |
| Corium, LLC | $293.27 | 2021-2025 | Azstarys |
| Kaleo, INC. | $230.75 | 2019-2024 | Auvi-Q |
| Cranial Technologies, INC | $188.36 | 2019-2025 | Doc Band |
| Neos Therapeutics, Lp | $146.71 | 2019-2024 | Adzenys Xr-Odt |
| Teva Pharmaceuticals USA, INC. | $126.65 | 2021 | |
| Sanofi Pasteur INC. | $114.01 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $109.88 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $108.28 | 2019-2024 | Jornay Pm |
| Ars Pharmaceuticals Operations, INC. | $108.00 | 2025 | Neffy |
| Adlon Therapeutics L.P. | $105.32 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $104.10 | 2020-2025 | Gardasil 9, Vaxneuvance, Rotateq |
| Tris Pharma INC | $91.47 | 2020-2025 | Dyanavel Xr |
| Alk-Abello, INC | $77.01 | 2025 | Neffy |
| Glaxosmithkline, LLC. | $76.93 | 2021-2023 | Bexsero, Rotarix, Pediarix |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $63.50 | 2021-2023 | Qelbree |
| Verrica Pharmaceuticals INC. | $44.28 | 2023-2024 | Ycanth |
| Collegium Pharmaceutical, INC. | $38.46 | 2025 | Jornay Pm |
| Arbor Pharmaceuticals, INC. | $27.42 | 2019 | |
| Pfizer INC. | $26.91 | 2024 | |
| Abbvie INC. | $25.76 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $23.87 | 2024 | Flumist Quadrivalent |
| Ultragenyx Pharmaceutical INC. | $21.90 | 2022 | |
| Seqirus USA INC | $21.71 | 2025 | Flucelvax |
| Allegis Pharmaceuticals, LLC | $17.55 | 2022 | |
| Genentech USA, INC. | $16.31 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Greg Cabrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.